Stereotaxis EBITDA 2010-2024 | STXS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Stereotaxis ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Stereotaxis ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$236.9B
Intuitive Surgical (ISRG)	$174.1B
Alcon (ALC)	$48.5B
IQVIA Holdings (IQV)	$44.6B
IDEXX Laboratories (IDXX)	$42.6B
Edwards Lifesciences (EW)	$40.5B
DexCom (DXCM)	$28.8B
STERIS (STE)	$23.6B
SONOVA HOLDING (SONVY)	$21B
Waters (WAT)	$20.1B
Hologic (HOLX)	$19.1B
Sysmex ADR (SSMXY)	$12.5B
Fresenius Medical Care AG KGaA (FMS)	$12.2B
Teleflex (TFX)	$11.6B
Globus Medical (GMED)	$9.6B
Penumbra (PEN)	$7.8B
Glaukos (GKOS)	$7.1B
Masimo (MASI)	$5.9B
TransMedics (TMDX)	$5.5B
Integer Holdings (ITGR)	$4.4B
PROCEPT BioRobotics (PRCT)	$4.3B
Tandem Diabetes Care (TNDM)	$2.9B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.7B
Inari Medical (NARI)	$2.6B
Elekta AB (EKTAY)	$2.5B
Nihon Kohden (NHNKY)	$2.3B
RxSight (RXST)	$2B
Integra LifeSciences Holdings (IART)	$1.4B
Pulse Biosciences (PLSE)	$1.1B